Ganesh babu MANOHARAN

Dr. Ganesh babu MANOHARAN

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
NSNiina M. Santio
Niina M. Santio
SLSebastian K.-J. Landor
Sebastian K.-J. Landor
LVLaura Vahtera
Laura Vahtera
JYJani Ylä-Pelto
Jani Ylä-Pelto
EPElina Paloniemi
Elina Paloniemi
Päivi J. KoskinenPäivi J. Koskinen
Päivi J. Koskinen
Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells

23 December 2019 in ACS Omega
Verified
Journal Article
Open access
FSFarid Ahmad Siddiqui
Farid Ahmad Siddiqui
CACatharina Alam
Catharina Alam
PRPetja Rosenqvist
Petja Rosenqvist
MOMikko Ora
Mikko Ora
ASAhmed Sabt
Ahmed Sabt
Daniel AbankwaDaniel Abankwa
Daniel Abankwa
The trafficking chaperone PDE6D (also referred to as PDEδ) has been nominated as a surrogate target for K-Ras4B (hereafter K-Ras). Arl2-assisted unloading of K-Ras from PDE6D in the perinuclear area is significant for correct K-Ras localization and therefore activity. However, the unloading mechanism also leads to the undesired ejection of PDE6D inhibitors. To counteract ejection, others have recently optimized inhibitors for picomolar affinities; however, cell penetration generally seems to remain an issue. To increase resilience against ejection, we engineered a “chemical spring” into prenyl-binding pocket inhibitors of PDE6D. Furthermore, cell penetration was improved by attaching a cell-penetration group, allowing us to arrive at micromolar in cellulo potencies in the first generation. Our model compounds, Deltaflexin-1 and -2, selectively disrupt K-Ras, but not H-Ras membrane organization. This selectivity profile is reflected in the antiproliferative activity on colorectal and breast cancer cells, as well as the ability to block stemness traits of lung and breast cancer cells. While our current model compounds still have a low in vitro potency, we expect that our modular and simple inhibitor redesign could significantly advance the development of pharmacologically more potent compounds against PDE6D and related targets, such as UNC119 in the future.

4 August 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
EGEnrico Glaab
Enrico Glaab
GMGanesh babu MANOHARAN
Ganesh babu MANOHARAN
Daniel AbankwaDaniel Abankwa
Daniel Abankwa
Among the biomedical efforts in response to the current coronavirus (COVID-19) pandemic, pharmacological strategies to reduce viral load in patients with severe forms of the disease are being studied intensively. One of the main drug target proteins proposed so far is the SARS-CoV-2 viral protease 3CLpro (also called Mpro), an essential component for viral replication. Ongoing ligand- and receptor-based computational screening efforts would be facilitated by an improved understanding of the electrostatic, hydrophobic, and steric features that characterize small-molecule inhibitors binding stably to 3CLpro and by an extended collection of known binders. Here, we present combined virtual screening, molecular dynamics (MD) simulation, machine learning, and in vitro experimental validation analyses, which have led to the identification of small-molecule inhibitors of 3CLpro with micromolar activity and to a pharmacophore model that describes functional chemical groups associated with the molecular recognition of ligands by the 3CLpro binding pocket. Experimentally validated inhibitors using a ligand activity assay include natural compounds with the available prior knowledge on safety and bioavailability properties, such as the natural compound rottlerin (IC50 = 37 μM) and synthetic compounds previously not characterized (e.g., compound CID 46897844, IC50 = 31 μM). In combination with the developed pharmacophore model, these and other confirmed 3CLpro inhibitors may provide a basis for further similarity-based screening in independent compound databases and structural design optimization efforts to identify 3CLpro ligands with improved potency and selectivity. Overall, this study suggests that the integration of virtual screening, MD simulations, and machine learning can facilitate 3CLpro-targeted small-molecule screening investigations. Different receptor-, ligand-, and machine learning-based screening strategies provided complementary information, helping to increase the number and diversity of the identified active compounds. Finally, the resulting pharmacophore model and experimentally validated small-molecule inhibitors for 3CLpro provide resources to support follow-up computational screening efforts for this drug target.

24 February 2014 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
RERamesh Ekambaram
Ramesh Ekambaram
EEErki Enkvist
Erki Enkvist
GMGanesh babu MANOHARAN
Ganesh babu MANOHARAN
MUMihkel Ugandi
Mihkel Ugandi
MKMarje Kasari
Marje Kasari
AUAsko Uri
Asko Uri
Benzoselenadiazole was used as a novel scaffold for construction of microsecond scale responsive photoluminescent probes for protein kinases.

26 May 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GMGanesh babu MANOHARAN
Ganesh babu MANOHARAN
SOSunday Okutachi
Sunday Okutachi
Daniel AbankwaDaniel Abankwa
Daniel Abankwa
Phenothiazines (PTZ) were developed as inhibitors of monoamine neurotransmitter receptors, notably dopamine receptors. Because of this activity they have been used for decades as antipsychotic drugs. In addition, they possess significant anti-cancer properties and several attempts for their repurposing were made. However, their incompletely understood polypharmacology is challenging. Here we examined the potential of the PTZ fluphenazine (Flu) and its mustard derivative (Flu-M) to synergistically act on two cancer associated targets, calmodulin (CaM) and the tumor suppressor protein phosphatase 2A (PP2A). Both proteins are known to modulate the Ras- and MAPK-pathway, cell viability and features of cancer cell stemness. Consistently, we show that the combination of a CaM inhibitor and the PP2A activator DT-061 synergistically inhibited the 3D-spheroid formation of MDA-MB-231 (K-Ras-G13D), NCI-H358 (K-Ras-G12C) and A375 (B-raf-V600E) cancer cells, and increased apoptosis in MDA-MB-231. We reasoned that these activities remain combined in PTZ, which were the starting point for PP2A activator development, while several PTZ are known CaM inhibitors. We show that both Flu and Flu-M retained CaM inhibitory activity in vitro and in cells, with a higher potency of the mustard derivative in cells. In line with the CaM dependence of Ras plasma membrane organization, the mustard derivative potently reduced the functional membrane organization of oncogenic Ras, while DT-061 had a negligible effect. Like DT-061, both PTZ potently decreased c-MYC levels, a hallmark of PP2A activation. Benchmarking against the KRAS-G12C specific inhibitor AMG-510 in MIA PaCa-2 cells revealed a higher potency of Flu-M than combinations of DT-061 and a CaM inhibitor on MAPK-output and a strong effect on cell proliferation. While our study is limited, our results suggest that improved PTZ derivatives that retain both, their CaM inhibitory and PP2A activating properties, but have lost their neurological side-effects, may be interesting to pursue further as anti-cancer agents.

1 October 2018 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JVJürgen Vahter
Jürgen Vahter
KVKaido Viht
Kaido Viht
AUAsko Uri
Asko Uri
GMGanesh babu MANOHARAN
Ganesh babu MANOHARAN
EEErki Enkvist
Erki Enkvist